Recruiting
Phase 3

Letermovir vs. Valganciclovir

Sponsor:

Virginia Commonwealth University

Code:

NCT06001320

Conditions

Kidney Transplant; Complications

CMV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Letermovir 480 mg once daily

Historical/Control

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-05. This information was provided to ClinicalTrials.gov by Virginia Commonwealth University on 2025-10-08.